Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjögren-associated myelopathy

Archives of Neurology

Volumn 63, Issue 9, 2006, Pages 1318-1320

  Pot, Caroline ^a   Chizzolini, Carlo ^a   Vokatch, Natalia ^a   Tiercy, Jean Marie ^a   Ribi, Camillo ^a   Landis, Theodor ^a   Perren, Fabienne ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TENOFOVIR;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; SPINAL CORD DISEASE; UNIVERSITY HOSPITAL;

ADENINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HTLV-I INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LAMIVUDINE; MAGNETIC RESONANCE IMAGING; METHYLPREDNISOLONE; MIDDLE AGED; PHOSPHONIC ACIDS; PREDNISONE; SJOGREN'S SYNDROME;

EID: 33748620014     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.9.1318     Document Type: Article

References (11)

1. Machuca A, Rodes B, Soriano V. The effect of antiretroviral therapy on HTLV infection. Virus Res. 2001;78:93-100.
2. Sasaki M, Nakamura S, Ohyama Y, et al. Accumulation of common T cell clono-types in the salivary glands of patients with human T lymphotropic virus type I-associated and idiopathic Sjogren's syndrome. J Immunol. 2000;164:2823-2831.
3. Green JE, Hinrichs SH, Vogel J, Jay G. Exocrinopathy resembling Sjogren's syndrome in HTLV-1 tax transgenic mice. Nature. 1989;341:72-74.
4. Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83:280-291.
5. Alexander GE, Provost TT, Stevens MB, Alexander EL. Sjogren syndrome: central nervous system manifestations. Neurology. 1981;31:1391-1396.
6. Hermisson M, Klein R, Schmidt F, Weller M, Kuker W. Myelopathy in primary Sjogren's syndrome: diagnostic and therapeutic aspects. Acta Neurol Scand. 2002;105:450-453.
7. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. "Sniffin' sticks": olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22:39-52.
8. Nakagawa M, Izumo S, Ijichi S, et al. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol. 1995;1:50-61.
9. Jeffery KJ, Usuku K, Hall SE, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A. 1999;96:3848-3853.
10. Vitali C, Bombardieri S, Jonsson R, et al; European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-558.
11. Gottenberg JE, Busson M, Loiseau P, et al. In primary Sjogren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum. 2003;48:2240-2245.